Recombinant ADAMTS13 in Severe Neonatal Thrombotic Thrombocytopenic Purpura
Open Access
- 22 December 2022
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (25) , 2391-2392
Abstract
Patients with hereditary thrombotic thrombocytopenic purpura (TTP), also known as the Upshaw–Schulman syndrome, have a genetic deficiency in the ADAMTS13 enzyme (1-3 Here, we report the case of a family in whom two neonates had been born with severe neonatal thrombotic microangiopathy, with death at day 3 after delivery in one infant and at day 14 after delivery in the other. Posthumous genetic analysis of the second neonate revealed pathogenic ADAMTS13 genetic variants (maternal c.1193G→A, p.Arg398His, and paternal c.3070T→G, p.Cys1024Gly) (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org).4Keywords
This publication has 5 references indexed in Scilit:
- Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndromeBlood Advances, 2019
- Characterization and treatment of congenital thrombotic thrombocytopenic purpuraBlood, 2019
- Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpuraBlood, 2017
- The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpuraNature, 2001